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The age-related pathological cascade underlying intraneuronal tau formation in 3xTg-AD mice, which harbor the human APPSwe,
PS1M126V , and TauP301L gene mutations, remains unclear. At 3 weeks of age, AT180, Alz50, MC1, AT8, and PHF-1 intraneuronal
immunoreactivity appeared in the amygdala and hippocampus and at later ages in the cortex of 3xTg-AD mice. AT8 and PHF-
1 staining was ﬁxation dependent in young mutant mice. 6E10 staining was seen at all ages. Fluorescent immunomicroscopy
revealed CA1 neurons dual stained for 6E10 and Alz50 and single Alz50 immunoreactive neurons in the subiculum at 3 weeks
and continuing to 20 months. Although electron microscopy conﬁrmed intraneuronal cytoplasmic Alz50, AT8, and 6E10 reaction
product in younger 3xTg-AD mice, straight ﬁlaments appeared at 23 months of age in female mice. The present data suggest that
otherage-relatedbiochemicalmechanismsinadditiontoearlyintraneuronalaccumulationof6E10andtauunderlietheformation
o ft a uﬁ l a m e n t si n3 x T g - A Dm i c e .
1.Introduction
During the last several years numerous transgenic animal
models of Alzheimer’s disease (AD) have been engineered to
examine the eﬀects of the two major AD neuropathological
hallmarks, amyloid plaques, and neuroﬁbrillary tangles
(NFT) on neurodegeneration. The vast majority of these AD
transgenic mice overexpress a mutant human amyloid-beta
(Aβ) precursor protein (APP) gene alone or in combination
with a mutated presenilin (PS) gene resulting in the presence
of brain extracellular amyloid plaques, which are mainly
formed by the accumulation of insoluble Aβ species [1–
6]. Since overexpression of amyloid-beta peptide did not
recapitulatealloftheneuropathologicalfeaturesofAD,addi-
tional models were created adding mutant tau transgenes.
For example, to further evaluate the pathogenic mechanisms
underlying NFT formation, transgenic mouse models have
been generated to harbor a mutant human tau gene found in
frontotemporal dementia or Pick’s disease (P301L or P301S).
These mutant mouse models display NFT-like structures
consisting of abnormal cytoskeletal tau protein aggregates
in the central and peripheral nervous systems [4, 7–10].
Recently, a triple transgenic mouse (3xTg-AD) harboring
the human APPSwe,P S 1 M146V,a n dT a u P301L gene mutations
was developed, displaying accumulation of both intracellular
Aβ and tau in an age-dependent manner within the cortex,
hippocampus, and amygdala [11–14], and to a lesser degree,
in the brainstem [15].
Immunohistochemical studies using immersion-ﬁxed
3xTg-AD mouse tissue have shown that intracellular
Aβ precedes the appearance of tau pathology, developing Aβ
deposits at 6 months and intraneuronal tau pathology at 9
monthsofage[11,12,14].Recentreportshavedemonstrated
that the development of Aβ plaques diﬀered between 3xTg-
A Dm o u s ec o l o n i e sa sw e l la sb e t w e e nm a l ea n df e m a l em i c e
[16, 17]. Furthermore, rostral-caudal diﬀerences in the onset
of tau pathology have been reported, but only in male 3xTg-
AD mice [17]. Virtually no ultrastructural analysis of AD
pathology in these mice has been described.
Therefore, in the present study we performed a system-
atic detailed evaluation of the evolution of tau conforma-
tion and phosphorylation events beginning at 3 weeks of2 International Journal of Alzheimer’s Disease
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Figure 1: Photomicrographs of 6E10, AT8, PHF-1, Alz50, and AT180 intraneuronal and neuropil immunostaining in the CA1 ﬁeld of
the hippocampus and basolateral nucleus of the amygdala (BLA) at 3 weeks, 2–4-, and 8-9-month-old male 3xTg-AD mice. Note the
diﬀerences in immunoreactivity between immersion and perfusion-ﬁxed tissue in 3-week-old 3xTg-AD mice for 6E10 ((a)–(d)), AT8 ((e)–
(h)), and PHF-1 ((i)–(l)). Alz50 ((m)–(r)) and AT180 ((s)–(x)) immunoreactivity was increased with age-dependent increases in the ventral
hippocampus, ((m), (o), (q), and (s), (u), (w)) and basolateral amygdala, ((n), (p), (r) and (t), (v), (x)). Abbreviation: DG: dentate gyrus.
Scale bar = 100μm.International Journal of Alzheimer’s Disease 3
age using perfusion-ﬁxed tissue at the light and electron
microscopic level to more completely deﬁne the cascade
of amyloid and tau pathology in male and female 3xTg-
AD mice. The data derived from this study provide novel
information underlying the temporal progression of amyloid
and tau pathology within the cortex, hippocampal/subicular
complex, and the amygdala that is pivotal in determining
the selective vulnerability of neurons during the life span
of male and female 3xTg-AD mice. This data is critical for
thedesignoffutureexperimentstoaddresspharmacological,
mechanistic, behavioral, and gender questions in studies
using this widely used mouse model of AD.
2.MaterialsandMethods
2.1. Transgenic Mice. A colony of homozygous 3xTg-AD
and nontransgenic (ntg) mice were generated from breeding
pairs provided by Dr. Frank LaFerla, University of California
Irvine. These transgenic mice harboring the human APPSwe,
PS1M146V,a n dT a u P301L mutations exhibit intraneuronal and
extracellularamyloidpathologyaswellastaupathology[12].
At least 4 male and 4 female juvenile (3 weeks), young (2-
3 months), adult (4–6 months), middle-aged (8-9 months),
and old (18–20 months) 3xTg-AD and non-transgenic (ntg)
mice were examined. In addition young, middle-aged and
oldfemale3xTg-ADmicewereusedforelectronmicroscopic
examination. Animal care and procedures were conducted
according to the National Institutes of Health Guide for Care
and Use of Laboratory Animals.
2.2. Fixation Protocol. Mice were anesthetized with an
injection of ketamine/xylazine (100mg/kg/5.0mg/kg) and
transcardiallyperfusedfor2minuteswith0.9%physiological
saline followed by a solution containing 4% paraformalde-
hyde and 0.1% glutaraldehyde in 0.1M phosphate buﬀer
(PB) for 5minutes (∼50ml) and then post-ﬁxed in the same
solution for 24hours at 4◦C. Since many transgenic mice
studies use immersion-ﬁxed brain tissue and considering
that tau antigenicity is time and ﬁxation sensitive [18–
26], another group of mice was transcardially perfused
with physiological saline and their brains hemisected and
immersion-ﬁxed for 24hours in the same ﬁxation solution.
All brains were cryoprotected in 30% sucrose, sectioned on
a sliding microtome at 40micron thickness, and stored in
a solution consisting of 30% glycerin, 30% ethylene glycol,
in 0.1M phosphate buﬀer at −20
◦C until processed for
immunohistochemistry.
2.3. Immunohistochemistry. Tissues from immersion or per-
fusion ﬁxed brains were processed as free-ﬂoating sections
and immunostained for anti-hAPP/Aβ reactive amino acid
residue 1–17 of beta-amyloid (6E10; 1:2,000 dilution,
Covance, N.J.), the tau conformational antibodies Alz50
(66kD), MC1 (66kD) (1:10,000, 1:250 dilution, resp.,
both gifts from Dr. Peter Davies, Albert Einstein School
of Medicine, N.Y.), and the phosphoepitope tau antibodies
AT180 (∼66 kD), AT8 (∼66 kD) (both at 1:1000 dilu-
tion, Thermoﬁsher, Waltham, MA) and PHF-1(57–67 kD)
(1:10000 dilution; gift from Dr. Peter Davies, Albert Einstein
College of Medicine) at each age examined. The speciﬁcity
of each of the antibodies used in this study was previously
characterized by western blot by others (6E10 (Covance),
AT180 [27, 28], AT8 [29], PHF-1 [30–32], Alz50 [33–36],
and MC1 [34, 35]). Prior to staining, sections were washed
3 × 10min in phosphate buﬀer and 3 × 1 0 m i ni nT r i s -
buﬀered saline (TBS) to remove cryoprotectant before a 20-
minute incubation in 0.1M sodium metaperiodate (Sigma,
St. Louis, MO) in TBS to quench endogenous peroxidase
activity. Tissue was then permeablized 3 × 10minutes in
TBS containing 0.25% Triton-X (Thermoﬁsher, Waltham,
MA) and blocked in the same solution containing 3% goat
serum for 1hour. Sections were incubated with appropriate
antibody dilutions overnight on an orbital shaker at 45 RPM
at room temperature in 0.25% Triton X-100, 1% goat serum
solution. The next day, tissue was washed 3 × 10min in
TBS containing 1% goat serum prior to incubation with
appropriate secondary antibody (see Table 1) at a 1:200
dilution for 1hr. Following 3 × 1 0m i n u t e sw a s h e si nT B S ,
sections were incubated in Vectastain ABC kit (Vector Labs,
Burlingame, CA) in TBS for 1hour. Tissue was then rinsed
3 × 10minutes in 0.2M sodium acetate, 1.0M imidazol
buﬀer, pH 7.4, and developed in acetate-imidazol buﬀer
containing 0.05% 3,3’-diaminobenzidine tetrahydrochloride
(DAB, Sigma, St Louis, MO). For comparison across ages
sections from animals of diﬀerent ages were immunostained
at the same time and with the same duration of DAB
reaction. The reaction was terminated in acetate-imidazol
buﬀer, tissue mounted on glass slides, dehydrated through
graded alcohols (70–95–100%, 3 × 5min), cleared in xylenes
(3 × 5min), and coverslipped with DPX (Biochemica Fluka,
Switzerland). Cytochemical control sections consisted of (1)
tissue from ntg mice which were processed in a manner
identical to the immunohistochemical procedures described
above for 3xTg-AD animals, (2) tissue from 3xTg-AD as
previously described with the exception of the primary
antibody, and (3) a preadsorption control consisting of a 100
fold amount of Aβ1-42 (US Peptides, Rancho Cucamonga,
CA) incubated with 6E10 in TBS containing 0.25% Triton
X-100, 1% goat serum overnight at room temperature. The
preadsorbed serum was used in place of the 6E10 antibody
in the immunohistochemistry protocol. Since the antigen
used to create the tau monoclonal antibodies obtained
from commercial sources was unavailable, only the 6E10
preadsorbtion control was performed. Brightﬁeld images
were acquired using a Nikon Optiphot microscope.
2.4. 6E10 and Alz50 Dual Immunoﬂuorescent Staining.
Selected sections were ﬂuorescently double-labeled for 6E10
and Alz50 using the above protocol with the following
modiﬁcations [15]. All steps prior to incubation of primary
antibody were as described above with the exclusion of the
quenching of endogenous peroxidase activity with 0.1M
sodium metaperiodate. Tissue was incubated with primary
antibody overnight (6E10; 1:200 dilution). After rinsing
3 × 10minutes in TBS, tissue was incubated with Cy3-
conjugated goat antimouse IgG Fcγ Subclass 1 speciﬁc
secondary antibody (Jackson Immunoresearch; West Grove,4 International Journal of Alzheimer’s Disease
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Figure 2: Schematic drawings representing the distribution of 6E10-ir neurons in 3-week, 2-, and 5-month-old perfusion-ﬁxed 3xTg-
AD transgenic mice. Note the age-related increase in the number of 6E10 positive neurons in the cortex, hippocampus, and amygdala.
Abbreviations: Aca: anterior commissure, anterior; aci: anterior commissure, intrabulbar, A: amygdala; AO: anterior olfactory nucleus; BLA:
basolateral nucleus of the amygdala; CA1: CA1 hippocampal subﬁeld; CA3: CA3 hippocampal subﬁeld; Cg: cingulate cortex; DG: dentate
gyrus; Ect: ectorhinal cortex; F: fornix; G: geniculate nucleus; lo: lateral olfactory tract; I: insular cortex, ic: internal capsule; m: motor cortex;
m:mammillarycomplex;ml:mediallemniscus;mt:mammillothalamictract;opt:optictract;PAG:periaqueductalgray,Pir:piriformcortex;
Pr:L prelimbic cortex; Rn: red nucleus; RS: retrosplenial cortex; S: sensory cortex; SC: superior colliculus; SN: substantia nigra; St: striatum;
Su: subiculum; th: thalamus; tu: olfactory tubercle. Small dots = 1–5 positive neurons, medium-size dots = 10–20 positive neurons, and large
dots = 100 positive neurons.International Journal of Alzheimer’s Disease 5
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Figure 3: Photomicrographs showing 6E10 intraneuronal immnostaining in the cortex ((a)–(c)), ventral CA1 ((d)–(f)), BLA ((g)–(i)), and
subiculum ((j)–(o)) in 3-week, 9- and 20-month-old 3xTg-AD mice. Round-or oval-shaped 6E10-ir neurons were found at the youngest
age in all brain regions examined independent of ﬁxation ((a), (d), (g)). At 9 months some 6E10 stained neurons appeared shrunken with
a hollow center ((b), (e), (h)). 6E10 immunopositive plaques were found throughout the subiculum of female (j), and to a lesser extent in
male mutant mice (m) at 20 months of age. Solid and dashed boxed areas in panels (j) and (m) outline a 6E10-ir plaque (k) and CA1-ir
neurons shown at higher magniﬁcation in (l) and (o), respectively. Dashed line in panel m demarks the CA1 ﬁeld from the subiculum.
Higher-power photomicorgraph shows a posterior subicular 6E10 positive plaque in a female 20-month-old mutant mouse (n). Tissue
processed following 6E10 antibody peptide preadsorbtion shows a lack of intra-or extraneuronal staining in CA1 or subiculum (P). Note the
more diﬀuse compared to the compact nature of plaques found in male-versus female-aged mutant mice. Ntg mice failed to display 6E10
immunoreactivity (c, f, i) at 3 weeks of age. Scale bar in ((a)–(i)); ((k), ((l), (n), (o)) = 20μm, ((j), (m)) = 100μm.6 International Journal of Alzheimer’s Disease
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Figure 4: Schematic drawings showing the distribution of Alz50-ir neurons at 3-week, 2-, and 5-month-old transcardially-ﬁxed 3xTg-AD
mice. Alz50-ir neurons were found mainly in the CA1 ventral hippocampus at 3 weeks of age. Note the increase in the number of Alz50-ir
hippocampal neurons in the 2- and 5-month old mutant mice. In addition there was an age-related increase in Alz-50 positive neurons
within the BLA. Abbreviations are the same as in Figure 2.S m a l ld o t s= 1–5 positive neurons, medium-size dots = 10–20 positive neurons,
and large dots = 100 positive neurons.International Journal of Alzheimer’s Disease 7
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Figure 5: Photomicrographs of Alz50-ir neurons in 3-week, 9- and 18-20-month-old 3xTg-AD mice. At 3 weeks of age scattered neurons
were found in the frontal parietal cortex (a) and BLA (g), whereas numerous Alz50-ir ventral hippocampal pyramidal cells were labeled (d).
By 9 months of age, neurons in the BLA and ventral hippocampus appeared shrunken (e) compared to the cortex (b). Numerous Alz50-ir
plaques and dystrophic neurites were found in the male ((j)-(k)) and female subiculum ((m)-(n)). Dashed boxes show higher magniﬁcation
images of dystrophic Alz50-ir CA1 pyramidal neurons ((l), (o)). Dashed line in panel (m) demarks the CA1 ﬁeld from the subiculum. Ntg
mice failed to show Alz50 immunoreactivity ((c), (f), (i)). Scale bar in ((a)–(i)); ((k), (l), (o)) = 20μm, ((j), (m)) = 100μm, and (n) = 30μm.8 International Journal of Alzheimer’s Disease
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Figure 6: Photomicrographs showing MC1 immunoreactivity within the hippocampal CA1 ﬁeld ((a)–(c)), BLA ((d)–(f)) and subiculum
((g)–(l)) at 3-week, 2–4-, 8-9-, and 20-month-old 3xTg-AD mice. Dashed line in (d) and (f) outlines the area containing the BLA. Note the
increase in MC1 neuronal immunostaining in hippocampal CA1 neurons ((b), higher magniﬁcation shown in insert), the neuropil in the
BLA (e) at 2–4 month and the reduction in reactivity in these areas in 9-month-old mutant mice ((c), higher magniﬁcation shown in insert
and (f)). Low-magniﬁcation images of the subiculum from male (g) and female (j) 20 months of old 3xTg-AD mice. Example of MC1-ir
neurites was observed in the subiculum of a male mutant mouse ((h)). Both male ((i)) and female ((j), higher magniﬁcation of boxed area
shown in (l)) mutant mice displayed dystrophic subicular MC1-ir neurons. Scale bars: ((a)–(f)); ((g), (J)) =100μm, insets = 35μm, ((h), (i),
(k), (l)) = 20μm.International Journal of Alzheimer’s Disease 9
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Figure 7: Schematic drawings showing the distribution of AT8-ir neurons in transcardially ﬁxed 3-week, 3-, and 6-month-old 3xTg-AD
mice. At 3 weeks, only scattered AT8-ir neurons were found in the cortex and basolateral amygdala compared to a greater number in the
ventralhippocampus.Notethatwithincreasingage,manymoreAT8-irwerefoundinthecortex,hippocampus,andamygdala.Abbreviations
are the same as in Figure 2. Small dots = 1–5 positive neurons, medium-size dots = 10–20 positive neurons, and large dots = 100 positive
neurons.10 International Journal of Alzheimer’s Disease
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Figure 8: Photomicrographs showing AT8 immunoreactivity in the cortex ((a)–(c)), ventral CA1, ((d)–(f)), BLA ((g)–(i)), and subiculum
((j)–(o)) in 3-week, 9-, and 18–20-month-old 3xTg-AD mice. Transcardially ﬁxed tissue revealed more AT8-ir neurons in the ventral
hippocampus than either the neocortex or BLA in 3-week-old 3xTg-AD mice ((a), (d), (g)). Note that AT8-ir neurons within the
hippocampus appeared shrunken with blunted dendrites at 9 months of age (e) when compared to younger (d) mutant mice. AT8
immunoreactive dystrophic neurons and plaques were observed in the subiculum of both male and female 20-month-old 3xTg-AD mice
((j)–(o)). Note the dystrophic neuronal morphology in male (k, arrow) and female (n, arrow) mice as well as the extent of tau pathology
((j), (m)). Dash line in m demarcates the boundary between the CA1 ﬁeld and the subiculum. (l) and (o) represent higher magniﬁcation of
boxed areas (j) and (m) respectively. Ntg 3-week-old mice displayed virtually no AT8 immunoreactivity ((c), (f), (i)). Scale bars: ((a)–(i));
((k), (l), (n), (o)) = 20μm and (j), (m) = 100μm.International Journal of Alzheimer’s Disease 11
20 months males 20 months females
3 weeks 3xTg-AD 9 mo 3xTg-AD 3 weeks ntg
C
o
r
t
e
x
V
e
n
t
r
a
l
 
C
A
1
A
m
y
g
d
a
l
a
S
u
b
i
c
u
l
u
m
(a) (b) (c)
(f) (e) (d)
(g)
(j) (m)
(o) (n) (l) (k)
(h) (i)
Figure 9:PhotomicrographsshowingAT180immunoreactivityinthecortex((a)–(c)),ventralCA1((d)–(F)),BLA((g)–(i)),andsubiculum
((j)–(o)) in 3xTg-AD mice. Note the more intense AT180-ir perinuclear staining (arrows), particularly in the BLA (h), and the shrunken
appearance of ventral hippocampal neurons (e) at 9 months of age when compared to 3 weeks of age ((d), (g)). Greater AT180-ir tau
pathology was observed in females than that in males at the CA1/subicular interface ((j), (m)). Higher magniﬁcation of dashed boxes in (j)
and (m) are represented in (l) and (o), respectively, while (n) represents higher magniﬁcation of solid box in (m). Ntg mice showed only
light background staining ((c), (f), (i)). Scale bars: ((a)–(i)); ((k), (l), (n), (o)) = 20μm and (j, m) = 100μm.12 International Journal of Alzheimer’s Disease
Table 1: Summary of Antibodies and Characterisitcs
Primary
Antibody Source Epitope and Isotype Secondary
Antibody Blocking Serum
Alz50
Dr. Peter Davies
Albert Einstein
College of
Medicine, NY
aa’s 5–15, 312–322;IgM
Goat-Anti mouse
IgG, Vector Labs,
Burlingame, CA
Goat; Gemini
Bio-Products,
West
Sacramento, CA
MC1
Dr. Peter Davies
Albert Einstein
College of
Medicine, NY
aa’s 5–15, 312–322;IgG1
Goat-Anti mouse
IgG, Vector Labs,
Burlingame, CA
Goat; Gemini
Bio-Products,
West
Sacramento, CA
AT180 ThermoFisher,
Walthman, MA
Phosphothreonine 231; IgG
1K
Goat-Anti mouse
IgG, Vector Labs,
Burlingame, CA
Goat; Gemini
Bio-Products,
West
Sacramento, CA
AT8 ThermoFisher,
Walthman, MA
Phosphoserine 202/205;
IgG 1
Goat-Anti mouse
IgG, Vector Labs,
Burlingame, CA
Goat; Gemini
Bio-Products,
West
Sacramento, CA
PHF-1
Dr. Peter Davies
Albert Einstein
College of
Medicine, NY
Phosphoserine 396/404;
IgG1
Goat-Anti mouse
IgG, Vector Labs,
Burlingame, CA
Goat; Gemini
Bio-Products,
West
Sacramento, CA
Aβ/APP
(6E10)
Covance
Princeton,NJ
aa’s 3–8 of Aβ seqeunce;
IgG 1
PA) for 2hours in the dark. Sections were washed 3 × 10
minutes in TBS and then incubated with Alz50 (1:1000)
overnightinthedark.Tissuewasagainrinsed3 ×10minutes
and then incubated in Cy2-conjugated goat antimouse IgM
μ-chain speciﬁc secondary antibody (1:200 dilution) for
2hours in the dark. Immunoﬂuorescence was visualized
using a Zeiss Axioplan 2 microscope using excitation ﬁlters
at wavelengths 489 and 555nm and emission ﬁlters at
505 and 570nm for Cy2 and Cy3, respectively. Florescent
images were stored on a computer and brightness and
contrast was enhanced using GIMP Version 2.6.7. Double
immunoﬂuorescence staining for 6E10 and phosphotau
markers were not successfully achieved using methods to
block the cross reactivity between monoclonal IgG1 subclass
primary antibodies (see Table 1).
2.5. Immunoelectron Microscopy. To determine ultrastruc-
tural localization of intraneuronal Aβ and tau immunore-
activity, we performed an immunoelectron microscopic
analysis of hippocampal/subicular neurons obtained from
female homozygous at 2- (n = 2), 9- (n = 2), and
23- (n = 2) month-old 3xTg-AD mice. Each animal
wastranscardiallyperfusedwith4%paraformaldehyde/0.1%
glutaraldehyde in phosphate buﬀer, brains were removed
from the skull and immersion post-ﬁxed in the same ﬁxative
overnight at 4◦C and cut into 80micron thick horizontal
sections using a Vibratome-1500 (Vibratome, Saint-Louis,
MO). Tissue containing the hippocampal/subicular complex
was immunostained using the antibodies directed against
Aβ/APP (6E10, 1:2000 dilution), the conformation speciﬁc
tau antibody Alz50 (1:10,000 dilution), and the phospho-
speciﬁc (Ser202/Thr205) antibody AT8 (1:1000 dilution).
T h ec h r o m o g e nD A Bw a su s e dt ov i s u a l i z ee a c ha n t i b o d y .
2.6. Transmission Electron Microscopy (TEM). Immunos-
tained sections were post-ﬁxed in 1% OsO4 for 45–
60minutes, dehydrated and embedded in Epoxy resin.
Immunoreactive proﬁles within the hippocampal/subicular
complex were selected using light microscopy, ultrathin
sections (50–70nm) were cut using a Leica Ultracut UCT
(Leica Microsystems Inc, Bannockburn, IL) microtome, and
the majority of sections counter-stained with 2% uranyl
acetate and lead citrate. TEM sections were viewed and
photographed with a JEOL transmission electron micro-
scope. Immunostaining appeared as an electron-dense pre-
cipitate (dark-black) in neurons and other proﬁles within
hippocampal-subicular complex of mutant mice. Cortical
brain tissue obtained at autopsy from an 82-year-old male
AD patient was immersion ﬁxed in 4% paraformaldehyde
and processed for TEM without antibody staining to com-
paretheultrastructureofhumanADpathologytothatfound
in 3xTg-AD mice.
3. Results
3.1. General Considerations. In the present study forebrain
sections from male and female 3-week, 2–4, 5-6, 8-9,
and 18–20-month-old 3xTg-AD and age-matched ntg mice
were immunostained using well-characterized antibodies
directed against 6E10, tau conformational epitopes (Alz50International Journal of Alzheimer’s Disease 13
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Figure 10: Photomicrographs showing PHF-1 immunostaining in cortex ((a)–(c)), hippocampus ((d)–(f)), BLA ((g)–(i)), and subiculum
((j)–(o)) in 3xTg-AD mice. PHF-1 immunostaining was seen almost exclusively in the ventral hippocampus of perfusion-ﬁxed brains
(d) compared to the cortex (a) and the BLA (g) at 3 weeks of age. By 8-9 months, many more PHF-1-ir neurons were apparent in
the hippocampus and BLA ((e), (h)). Only scattered PHF-1-ir neurons were found in the neocortex at this age (b). Many more PHF-1
immunopositive neurons appeared in the dorsal anterior CA1 region of female mutant mice (area outline by dashed line in M and shown at
higher magniﬁcation (o)) compared to males (area outline by dashed line in (j) and shown at higher magniﬁcation in (l)) at 18–20 months
of age. PHF-1 immunopositive plaques were seen in the subiculum of male (solid boxed area in (j) and (k)) and female (solid boxed area
in (m) and (o)) 3xTg-AD mice at 18–20 months of age. Note that the extent of PHF-1 immunoreactivity was greater in the subiculum in
females (M) versus males (J). PHF-1-ir proﬁles were absent in ntg mice ((c), (f), (i)). Scale bars: (a)–(i); ((k), (l), (n), (o)) = 20μm and ((j),
(m)) = 100μm.14 International Journal of Alzheimer’s Disease
(a) (b) (c)
(f) (e) (d)
(g) (h) (i)
6E10          Alz50          Merge         
CA1
CA1 CA1
CA1 CA1 CA1
CA1
CA1
Sub
Sub Sub
Sub Sub Sub
Sub
Sub
Sub
CA1
3
 
w
e
e
k
s
 
9
 
m
o
n
t
h
s
 
1
9
 
m
o
n
t
h
s
 
Figure 11: Immunoﬂuorescent microscopic images showing single and dual 6E10 and Alz 50 staining in the hippocampal CA1 ﬁeld and the
subiculum of 3xTg-AD mice. Images of single 6E10 immunolabeled ((a), (d), and (g), red), (b), (e), (h) (Alz50, green) and merged (yellow,
(c), (f), (i)) neurons at 3-week, 9- and 19-month-old 3xTg-AD mice. Note that 6E10 immunolabeled neurons are found in both the CA1
and subiculum but only Alz50 immunolabeled neurons were seen in CA1 at each age examined. The merged images show that many CA1
neurons contained both 6E10 and Alz50 immunoreactivity whereas the subicular neurons were only 6E10 positive at each age examined
within Alz50-ir neuropil. Scale bar for (a)–(i) = 75μm.
and MC1), and phosphotau epitopes AT180 (phospho-
threonine 231), AT8 (phosphoserine 202/205), and PHF-1
(phosphoserine 396/404). In general, an age-related increase
in intraneuronal and neuropil immunoreactivity in the
hippocampal-subicular complex and amygdala were seen
for all antibodies examined (Figure 1). The exception was
MC1, where immunoreactivity decreased after 2–4 months
of age (see Figure 6). Our ﬁndings revealed that transcardial
but not immersion ﬁxation dramatically enhanced the
immunovisualization of AT8 (Figures 1(e)–1(h)) and PHF-
1 (Figures 1(f)–1(l)) as early as 3 weeks of age. By contrast,
AT180 and Alz50 immunoreactivity was not aﬀected by the
ﬁxation procedure. Therefore all morphological analyses and
photomicrographs subsequent to Figure 1 were derived from
transcardiallyﬁxedtissue.Thecolocalizationof6E10andtau
antibodies using ﬂuorescence was achieved successfully for
6E10 (IgG1) and Alz50 (IgM), but not for 6E10 and AT180
(IgG1) or AT8 (IgG1) due to the cross reactivity of theirInternational Journal of Alzheimer’s Disease 15
primary antibodies. Therefore, the comparative analyses of
the distribution of 6E10 and phosphotau markers were
performed using DAB-reacted tissue sections at the light
microscopic level. All immunohistochemical controls failed
to display cellular or plaque reactivity beyond background
levels for any tau antigen or 6E10 independent of ﬁxation,
age, and gender.
3.2. Staging 6E10 Immunoreactivity. The 6E10 antibody,
which recognizes amino acids 3–8 of the Aβ sequence,
revealedthegreatestnumberandtopographicdistributionof
immunoreactive (-ir) neurons in 3xTg-AD mice compared
to the other antibodies we examined. There was an age-
related increase in the extent of 6E10-ir neurons in all
regions examined (Figure 2). Beginning at 3 weeks of age,
intraneuronal 6E10-ir neurons were found in lamina 3
and 5 of the fronto-parietal cortex, deep layers of the
cingulate cortex, CA ﬁelds of the hippocampus, subiculum,
and the basolateral amygdala (BLA) in 3xTg-AD mice at
each age independent of gender (Figure 2). 6E10-ir neurons,
particularly in the hippocampal CA1 subﬁeld, appeared
round or oval in shape with many cells showing a thin
ringofimmunoreactivitylocatedwithinthesomatodendritic
compartment (Figures 3(a), 3(d), and 3(g)). However, a
number of cells in the cortex and amygdala had thickened
perinuclear staining (Figures 3(d) and 3(a)), which became
more prominent by 9 months of age (Figure 3(b) and 3(h)).
Beginning at 9 months of age there was neuronal shrinkage
of 6E10-ir neurons in 3xTg-AD mice (Figures 3(b), 3(e), and
3(h)), which continued at least until 18–20 months of age
where many neurons displayed blunted dendrites, as well.
Although no dramatic gender diﬀerences in intraneu-
ronal6E10stainingwereseenpriorto8-9months,Aβ plaque
deposits were visualized for the ﬁrst time in the subiculum
of 8-9-month-old female, but not male mutant mice (data
not shown). By 18–20 months both genders displayed Aβ
plaque deposits in the subiculum (Figures 3(j), 3(k), 3(m),
and 3(n)) and hippocampus (data not shown). Aβ plaques
appeared smaller and more diﬀuse in male than seen in the
female subiculum of 3xTg-AD mice (Figures 3(j) and 3(k)).
In fact, female CA1 neurons lost their dendritic 6E10-ir
extensions into the substantia radiatum (Figure 3(o)) while
similar processes remained present in male mutant mice
(Figures 3(l) and 3(o)).
3.3. Staging of Tau Pathology
3.3.1. Alz50 Immunoreactivity. The Alz50 antibody recog-
nizes an early stage conformational tau epitope that labels
neurons undergoing early degenerative events associated
with NFT formation but has also been shown to label
neurons in normal brains [33–37]. Similar to 6E10 staining,
the number of Alz50-ir neurons increased with age in
all regions examined (Figure 4). As early as 3 weeks of
age Alz50-ir staining was seen predominantly within the
more caudal and ventral aspects of the hippocampal CA1
pyramidal and subicular neurons, whereas a few scattered
Alz50-ir neurons were found in the neocortex and BLA
(Figures 4(a)–4(d)). In addition, Alz50-ir neurons were
also found in the septal but not temporal portions of the
hippocampal formation (data not shown). Beginning at 2–
4 months of age a few scattered Alz50-ir neurons were
found in layers 3 and 5 of the fronto-parietal and the deep
layers of the cingulate and retrosplenial cortex in 3xTg-AD
mice (Figures 4(e)–4(h)). By 5-6 months of age there was
an apparent increase in the number of Alz50-ir neurons
in the ventral hippocampus and amygdala (Figures 4(i)-
4(l)), as well as more intense neuropil staining (Figures 1(q)
and 1(r)). However, unlike the continuous distribution of
6E10-ir pyramidal neurons in the hippocampal complex, the
topographic distribution of labeled Alz50-ir CA1 pyramidal
neurons spread in dorsal and anterior directions from the
ventral and caudal regions of the brain (Figure 4). At 3 weeks
of age Alz50-ir neurons in the cortex, hippocampus, and
amygdala appeared round or oval and displayed a dense rim
of perinuclear staining (Figures 5(a), 5(d), and 5(g)) with
long dendrites extending into the neuropil. At 9 months
of age many Alz50-ir neurons appeared shrunken with a
distorted cellular morphology in the hippocampal complex
and amygdala (Figures 5(e) and 5(h)). Interestingly, some
cells no longer displayed perinuclear staining but became
completely ﬁlled with Alz50 reaction product (Figure 5(h))
or were dystrophic (data not shown). While the presence
of Alz50-ir dystrophic neurites appeared concomitantly with
the onset of Aβ plaque deposition between 8 and 9 months
of age in female mutant mice, dramatic diﬀerences between
male and female Alz50 staining were only apparent by 18–
20 months of age. The dorsal and anterior subicular region
adjacent to the CA1 neurons was most aﬀected with Alz50-
ir dystrophic neurites in male and female 18–20-month-
old 3xTg-AD mice (Figures 5(j) and 5(m)). In general,
numerous large and globular dystrophic Alz50-ir neurites
were seen surrounded by plaques in both male and female
mice (Figures 5(m) and 5(n)). In female transgenic mice
many plaques displayed a rim of dark Alz50-ir dystrophic
neurites with a clear center (Figure 5(k)), while in males
this neuritic organization was less obvious (Figure 5(n)).
In addition, in 18–20-month-old female 3xTg-AD mice
dark, swollen, Alz50-ir dystrophic neurons were found in
abundance among more lightly stained CA1 pyramidal
cells (Figures 5(m) and 5(o)). Furthermore, the amygdala
displayed similar neuronal perinuclear staining in male and
female transgenic mice with an occasional rim of Alz50-
ir dystrophic neurites surrounding plaques only in female
mutant mice (data not shown).
3.3.2. MC1 Immunoreactivity. The MC1 antibody recognizes
early stage conformational epitopes similar to Alz50 but does
not react with normal neuronal tau [34, 35, 37]. In contrast
to Alz50 staining, lightly stained MC1-ir neurons were found
only in the CA1 pyramidal cells of the ventral hippocampus
in 3-week-old 3xTg-AD mice (Figure 6(a)). By 2–4 months,
lightly stained MC1-ir neurons were seen throughout the
CA1 subﬁeld of the ventral hippocampus (Figure 6(b)).
A few darkly stained MC1 neurons were seen, some of
which appeared shrunken with blunted dendrites within
the hippocampus. On the other hand, no MC1-ir neurons
were seen in the BLA at 3 weeks of age (Figure 6(d)). In16 International Journal of Alzheimer’s Disease
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Figure 12: Light microscopic images of adjacent sections showing 6E10, AT180, and AT8 immunoreactive proﬁles in CA1 and subiculum
in 3-week, 9-, and 18–20-months-old 3xTg-AD mice. AT180 and AT8 immunostained CA1 and subicular neurons were present at each
age examined. This is in contrast to the Alz50, which only stained neurons in the CA1 ﬁeld (see Figure 11). The arrows in F and I indicate
dystrophic AT8 subicular neurons. Dashed line in (i) demarcates the CA1 ﬁeld from the subiculum. Scale bar in (a) is the same for all panels
= 50μm.
2–4-month-old mutant mice, scattered round-or-oval
shaped lightly stained MC1-ir neurons were found
embedded within the MC1 immuopositive neuropil of
the BLA. Interestingly, MC1-ir neuropil and neuronal
labeling decreased in the hippocampus and BLA in 8-9-
month-old mutant mice (Figures 6(c) and 6(f)). MC1-ir
proﬁles were not detected in the neo- and limbic cortex up to
9 months of age. By 18–20 months, MC1 labeling matched
Alz50 immunoreactivity in male and female 3xTg-AD
mice. Although plaque-like structures were hard to detect,
globular MC1-ir dystrophic neurites and neurons were
found mainly throughout the female subiculum (Figures
6(j), 6(k), and 6(l)). Some dystrophic neurons appeared
to have eccentrically located dark cytoplasmic neuronal
inclusions (Figures 6(i), 6(k), and 6(l)).
3.3.3. AT8 Immunoreactivity. Hyperphosphorylated micro-
tubule-associated protein tau is the major component of theInternational Journal of Alzheimer’s Disease 17
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Figure 13: Electron microphotographs showing neuritic plaques (p) surrounded by numerous dystrophic neurites (dotted-red circles)
in tissue sections through the hippocampal-subicular complex of a 9-(A) and 23-(B) month-old 3xTg-AD female mouse. Boxed area (a)
shows details of the ﬁbrillar material from amyloid plaque in A. a  shows an example of a dystrophic neurite from a 9-month-old 3xTg-AD
containing electron-dense multilaminar, multivesicular, and dense-core bodies similar to that seen in the cortex of a patient with AD (D).
Note that at 23 months of age neuritic plaques show an electron dense center core (B) with numerous ﬁbrillar branches (b) similar to a
neuritic plaque seen in AD (c). Abbreviation: n: nucleus. Scale bars: A = 2 μm, B = 5 μm, C, a, b = 0.5μm, and D, a  =1μm.
paired helical ﬁlament seen in the NFT. The monoclonal
antibody AT8 marks tau phosphorylation at both serine
202 and threonine 205 [29]. AT8-ir neurons were found
in the neocortex, amygdala, and hippocampal formation
in both male and female 3xTg-AD mice at all ages exam-
ined (Figure 7). Like the distribution of Alz50-ir neurons,
hippocampal and subicular regions contained the highest
number of AT8-ir neurons compared to the cortex and
amygdala in 3-week-old 3xTg-AD mice (Figures 7(a)–7(d)).
A few AT8-ir neurons were observed in layer 5 of the fronto-
parietal cortex and BLA (Figures 7(a)–7(c)). As mutant mice
age, the extent of neuronal AT8 labeling in the hippocampal
complex increased in a ventral to dorsal and posterior to
anterior gradient (Figures 7(e)–7(l)), but unlike the Alz50-
ir proﬁles at 5-6 months of age, anterior portions of the
hippocampal complex did not appear to be aﬀected (Figures
7(c), 7(g), and 7(k)). At 3 weeks of age, AT8-ir neurons
displayed more diﬀuse cytoplasmic staining in the cortex,
hippocampus, and BLA (Figures 8(a), 8(d), and 8(g)), rather
than the dense perinuclear staining observed in Alz50-ir
neurons in these regions. However by 9 months of age AT8-
ir neurons appeared shrunken, distorted, and showed thicker
perinuclear staining, especially in the amygdala (Figures
8(b), 8(e), and 8(h)). Some neurons in the hippocampus
(Figure 8(e)), BLA (Figure 8(h)), and subiculum displayed
blunted AT8-ir dendrites. AT8 dystrophic neurons were
more abundant in the female subiculum and constituted
the greatest diﬀerence between male and female pathology
at 18–20 months of age (Figures 8(j)–8(o)). While the
entire extent of the female subiculum showed numerous
AT8-ir dystrophic neurites, the male subiculum contained
lessneuriticdystrophy(Figure 8(j)versusFigure 8(m)).AT8-
ir pyramidal cells displayed an asymmetric accumulation of
dense perinuclear staining (Figures 8(k) and 8(o)), and AT8-
ir dystrophic neurites were associated with plaques (Figures
8(l), 8(n)).
3.3.4. AT180 Immunoreactivity. AT180 detects tau phospho-
rylation at the Thr231 site, an early event in the assembly of
tau into ﬁlaments [27, 28]. AT180-ir neurons displayed the
greatest number and spatial distribution of all tau antibodies
examined at 3 weeks of age in 3xTg-AD mice. AT180-ir
neurons were found in layer 5 of the fronto-parietal cortex,
BLA, CA1 ventral hippocampus, and subiculum (Figures
9(a), 9(d), and 9(g)). Qualitatively there was an age-related
increase in the number of AT180-ir neurons within each
brain region examined as well as in the intensity of neuropil
staining in the ventral hippocampus and BLA (Figures 1(s)–
1(x)). At 3 weeks of age AT180 immunostaining appeared
as diﬀuse cytoplasmic reactivity in round or oval pyramidal
cells of the neocortex, hippocampus (Figures 9(a) and 9(d))
and BLA (Figure 9(g)) in 3xTg-AD mice. Some neurons
embedded in the CA1 pyramidal cell layer, BLA, and
subiculum displayed perinuclear staining (Figures 9(d) and
9(g)).By9months, AT180-ir hippocampal andBLAneurons
revealed blunted staining in dendrites (Figure 9(e)). In the
BLA, a number of neurons exhibited thickened perinuclear
staining (Figure 9(h)). Diﬀerences between male and female
AT180 staining occurred in the hippocampal CA1 neurons
and the subiculum at older ages. Speciﬁcally, at 18–2018 International Journal of Alzheimer’s Disease
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Figure 14: Electron photomicrographs showing perinuclear and cytoplasmic 6E10 immunoreactivity (black arrows) in hippocam-
pal/subicular complex neurons at 2- (a) and 9- (b) month-old 3xTg-AD mice. Micrographs showing scattered Alz50 (c) and AT8 (d)
immunoreactivity in hippocampal/subicular complex neurons in 2-month-old 3xTg-AD mice, whereas at 9 months Alz50 (e) and AT8 (f)
immunoreactivitywasincreased,withouttheformationofﬁlamentsasseeninAD(g).Boxedareashowsahigher-magniﬁcationphotograph
of the morphology of paired helical ﬁlaments in the AD brain (h). Photomicrographs of Alz50 ((i) and (j)) and AT8-ir ((k)–(m)) ﬁlaments
in hippocampal/subicular complex neurons at 23 months in the 3xTg-AD mouse. J, Panel shows detail of straight Alz50-ir ﬁlaments from
the white boxed area in (i). (l) and (m) areas containing AT8-ir ﬁlaments are outlined in white in panel k showing AT8 positive ﬁlaments
in cross (l) and longitudinal (m) proﬁle. Abbreviation: n: nucleus. Scale bars in (a), (b), (g) =2μm, (c), (d), (f), (k) = 1μm, (e), (i), (h) =
0.5μm and (j), (l), (m) = 200nm.
months of age AT180-ir dystrophic neurites were more
widespread within the subiculum in female compared to
male 3xTg-AD mice (Figures 9(j) and 9(m)). However,
in male mice, AT180-ir dystrophic pathology was mainly
found in the subiculum closest to the border with the CA1
pyramidal cell layer. In addition, CA1 pyramidal neurons
displayed a dense perinuclear staining and blunted dendrites
(Figures 9(l) and 9(o)).
3.3.5. PHF-1 Immunoreactivity. PHF-1 recognizes tau phos-
phorylated at serine residues 396 and 404 and is generally
considered a late marker in the evolution of PHF positive
NFTs [30–32]. At 3 weeks of age only a few lightly stained
PHF-1-ir neurons were observed in the CA1 region of the
ventral hippocampus and the BLA in perfusion ﬁxed 3xTg-
AD mice (Figures 10(d) and 10(g)). At 2-3 months, a few
PHF-ir neurons were seen at the CA1/subicular interface of
the dorsal hippocampus (data not shown). By 9 months, the
number of PHF-1-ir ventral hippocampal CA1 pyramidal
and BLA neurons increased (Figures 10(e) and 10(h)). The
distribution of PHF-ir neurons in the hippocampal complex
followed a ventral to dorsal gradient. Up to 9 months of age,International Journal of Alzheimer’s Disease 19
an occasional PHF-1-ir neuron was visible in the neocortex
(Figure 10(b)). PHF-1 dystrophic neurons and neurites were
more prevalent in the subiculum of aged females (Figures
10(m)and10(n))comparedtoagedmales(Figures10(j)and
10(k)). PHF-1-ir CA1 neurons displayed distorted cellular
morphology, with broken, asymmetric, but strongly stained
perinuclear staining in the female subiculum (Figure 10(o)).
Incontrast,PHF-1-irneuronsinthemalesubiculumshowed
similarly stained dark neurons but retained somatodendritic
staining (Figure 10(l)).
3.4. Colocalization of 6E10 and Alz50 Immunoreactive Neu-
rons. Toevaluatewhetherneuronsexpressing6E10alsocon-
tained tau epitopes we performed dual immunoﬂuorescence
and comparative light microscopic experiments on adjacent
hippocampal subicular sections at 3-week, 9-, and 18–20-
month old male and female 3xTg-AD mice. Although it
would have been interesting to double stain for 6E10 and
other tau makers (AT180 and AT8), all three antibodies
are murine IgG1s. Therefore, dual immunoﬂuorescence
experiments were performed only for 6E10 and Alz50, an
IgM. In these experiments we observed two bands of 6E10
immnoreactivitylocatedwithinventrallylocatedwithinCA1
hippocampal and subiculum neurons of female mutant mice
at all ages examined (Figures 11(a), 11(d), and 11(g)).
By contrast, Alz50-ir neurons were only observed in the
CA1 pyramidal cell layer, and as neuropil staining in the
subiculum (Figures 11(b), 11(e), and 11(h)). In general,
Alz50-ir neurons were found to be colocalized with 6E10-ir
neurons at each age examined in the ventral hippocampus
(Figures 11(c), 11(f), and 11(i)).
Because 6E10, AT180, or AT8 are all of the murine
IgG1 subclass, adjacent sections through the CA1 and
subicular ﬁelds were reacted with individual antibodies and
visualized using peroxidase/DAB. In contrast to the single
layer of Alz50-ir neurons in the CA1 pyramidal cell layer
(Figures 12(b), 12(e), and 12(h)), numerous AT180, AT8,
and 6E10 immunopositive neurons were seen in both CA1
and subicular ﬁelds in the ventral hippocampus at each age
examined (Figure 12).
3.5. Ultrastructural Analysis of Amyloid and Tau Containing
Structures in 3xTg-AD Mice. At the ultrastructural level,
unstained tissue sections revealed plaques within the hip-
pocampal/subicular complex that displayed numerous ﬁbril-
lar branches, which were surrounded by dystrophic neurites
in 9-month-old 3xTg-AD mice (Figure 13(a)). In 23-month-
old female 3xTg-AD mice, the majority of neuritic plaques
displayed a central core surrounded by many more ﬁbrillar
branches and dystrophic neurites, similar to that seen in
human AD plaques (Figure 13(c)). The neuropil contained
dystrophic neurites of diﬀerent sizes displaying various
accumulations of electron-dense cytoplasmic material, mul-
tilaminar, multivesiclular, and dense-core bodies in both 9-
and 23-month-old 3xTg-AD mice (Figures 13(a) and 13(b)),
similar to that seen in an AD plaque (Figure 13(d)). TEM
analysis of intraneuronal 6E10 immunoreactivity revealed
staining mainly conﬁned to the periphery of the nucleus
within CA1 hippocampal/subicular neurons in 2-month-
old 3xTg-AD mice (Figure 14(a)). At 9 months of age this
perinuclear 6E10 reaction product appeared more intense
and extended into the cytoplasm (Figure 14(b)).
Attheultrastructurallevel,Alz50andAT8-irwereseenin
the soma and dendrites of CA1 neurons in female 2-month-
old mutant mice (Figures 14(c) and 14(d)). Intraneuronal
electron dense Alz50 and AT8-ir cytoplasmic staining was
more widespread and increased in intensity in 9 month-
old-mutant mice (Figures 14(e) and 14(f)). Interestingly,
cytoplasmic Alz50-ir appeared more extensive than AT8
immunoreactivity in these neurons at both 2 and 9 months
of age (Figures 14(c), 14(d), 14(e), and 14(f)). Despite the
presence of AT8 and Alz50-ir cytoplasmic labeling within
hippocampal/subicular CA1 neurons, TEM failed to reveal
any type of ﬁlamentous aggregates in 2- or 9-month-old
3xTg-AD mice (Figures 14(c), 14(d), 14(e), 14(f), 14(l),
and 14(m)). In contrast, at 23 months of age both male
and female 3xTg-AD mice displayed Alz50 and AT8-ir
straight ﬁlaments with a 19–20nm diameter within the
hippocampal-subicular complex (Figures 14(i)–14(m)).
4. Discussion
Previous studies have shown widespread amyloid but not tau
pathology at 6 months of age in the hippocampus [3, 12,
13, 17], and behavioral studies using the Morris Water Maze
have demonstrated memory retention deﬁcits dependent
upon the appearance of amyloid pathology at 6- but not 2-
month-old 3xTg-AD mice [11]. Our study found that (1)
the appearance of 6E10 immunoreactivity was concomitant
with conformation (Alz50 and MC1) and phosphorylation
(AT8, AT180, and PHF-1) events in the neurons of the
hippocampal-subicular complex and amygdala as early as 3
weeks of age; (2) the detection of the two phospho-epitopes
AT8 and PHF-1 was ﬁxation dependent at all ages; (3) the
number of Aβ plaques, as well as neuritic and neuronal
dystrophy, increased with age in the cortex, hippocampus,
and subicular area in 3xTg-AD mice; (4) aged female mice
displayed more plaque and tau pathology than aged male
3xTg-AD mice; and ﬁnally (5) straight tau ﬁlaments were
found only in 23-month-old female 3xTg-AD mice.
In the present study, 6E10-ir neurons were seen as
early as 3 weeks of age in lamina 3 and 5 of the fronto-
parietal cortex, deep layers of the cingulate cortex, CA1
pyramidal neurons of the hippocampus, subiculum, and
BLA in 3xTg-AD mice independent of gender. These data
indicate that intraneuronal 6E10 immunoreactivity occurs
extremely early in the development of these mice (3 weeks)
and are in contrast to previous investigations showing that
6E10 intraneuronal staining occurred between 3 and 6
months of age in the hippocampus of these mice [12, 17].
Because the 6E10 epitope resides in amino acids 3–8 of the
N-terminal portion of the Aβ sequence, it does not preclude
binding to full length APP or its amyloidgenic derivatives.
Consequently, the exact amyloid species revealed within
neurons at 3 weeks of age in 3xTg-AD mice and at other
agesexaminedisunclear.OligomericAβ speciesmay,inpart,
underlie cellular degeneration [3, 11, 38–48].20 International Journal of Alzheimer’s Disease
We also observed many shrunken 6E10-ir neurons
beginning at 8-9 month of age in each brain area examined
in both male and female 3xTg-AD mice. This phenotype
was most pronounced in CA1 hippocampal neurons of
older female 3xTg-AD mice. These neurons exhibited loss
of dendritic 6E10 immunoreactivity when compared to CA1
neuronsinmalemutantmice.ThesegenderdiﬀerencesinAβ
intraneuronal pathology lend support to prior investigations
showing that female 3xTg-AD mice display earlier and more
severe plaque pathology [16], which may be related to pro-
gesterone and estrogen-mediated signaling [49]. However,
other factors may contribute to the discrepancies in AD-
like pathology reported in studies using diﬀerent colonies
of 3xTg-AD mice, including a loss of phenotype related
to successive breeding, founder eﬀects between colonies,
or diﬀerential expression of transgenes [16]. Together or
separately, variations in transgenic animal strain or amyloid
species may aﬀect both pathological and behavioral observa-
tions reported in studies using 3xTg-AD mice.
Of interest was the observation that the immunohisto-
chemical localization of phosphospeciﬁc tau proteins AT8
and PHF-1 was ﬁxation dependent, whereas Alz50, MC1,
AT180, and 6E10 immunoreactivity was ﬁxation indepen-
dent in young, juvenile, and middle age 3xTg-AD mice.
Notably, neurons containing the phospho-epitope AT8 were
seen in layer 5 of frontoparietal cortex, ventral hippocampal
pyramidal, and amygdala neurons, whereas PHF-1-ir intra-
neuronal staining was seen only in the ventral hippocampus
in perfusion-ﬁxed 3-week-old 3xTg-AD mice. Previous
biochemical and immunohistochemical studies indicate that
ﬁxative composition aﬀects the ability to detect various
cytoskeletalproteins[18,22,23].Theprocessofaldehydeﬁx-
ationreliesupon aslowcross-linking ofcarbonylaldehydeto
functional protein groups. While perfusion ﬁxation rapidly
exposes proteins to ﬁxative through the vasculature, immer-
sion ﬁxation relies upon a slow 1mm per hour diﬀusion
rate to penetrate tissue [20]. It is possible during immersion
ﬁxation that proteolysis or dephosphorylation of the tau
phospho-epitopes recognized by AT8 and PHF-1 occurs
prior to the full penetration of the ﬁxative. Since immersion-
ﬁxed tissue reacts with C-terminal, N-terminal, and internal
tau antibodies, proteoloysis of tau is unlikely [25, 50]. A
more plausible possibility is the destruction of AT8 and
PHF-1 epitopes by the action of endogenous phosphatases
during slow immersion ﬁxation [51–53]. However, AT180
immunoreactivity remained robust even in immersion-ﬁxed
tissue. Likely, phosphatases act diﬀerentially depending on
the individual tau phosphoepitopes [54]; hence, it is possible
that the AT180 phospho-epitope is less sensitive to phos-
phatase activity than either AT8 or PHF-1 phosphorylation
sites, resulting in a more robust staining in immersion-ﬁxed
tissue.Althoughlongpostmortemintervalsreducephospho-
tau antigenicity due to active phosphatases, [19, 50, 55],
this was not a confounding variable in the present study
since all animals were sacriﬁced and perfused with ﬁxative
within 5 minutes of anesthetization. The potential eﬀect of
ﬁxationontheimmunolocalizationoftauandotherproteins
[56] represents an important caveat that may provide an
explanation for the underlying diﬀerences in tau antigenicity
reported in previous studies using the 3xTg-AD mouse
model [3, 12–14, 16, 57, 58].
Although a previous report described intraneuronal
MC1-ir CA1 dorsal hippocampal neurons only in 12–15-
month-old 3xTg-AD mice [12], the present study displayed
weak MC1 immunoreactive neurons in the ventral hip-
p o c a m p u se v e na se a r l ya s3w e e k so fa g e .W ea l s oo b s e r v e d
Alz50 immunoreactive CA1 pyramidal and subicular neu-
rons in the ventral aspect of the hippocampal/subicular
complex at 3 weeks of age. Although both MC1 and Alz50
antibodies recognize similar epitopes, they are not identical.
Overall, Alz50 immunoreactivity was much more intense
and labeled a greater distribution of immunoreactive neu-
rons than with the MC1 antibody. While Alz50 immunore-
activity increased in an age dependent manner in the neo-
cortex,hippocampus,andamygdala,MC1immunoreactivity
exhibitedabiphasicresponse,peakinginitiallybetween2and
4 months, declining at 9 months and then peaking again at
18–20 months in numerous swollen, tangle-like appearing
CA1 hippocampal and subicular neurons. Interestingly, both
MC1andAlz50-ir neurons werefoundinthe CA1pyramidal
but not the subicular cell layer in the ventral hippocampal
formation at the ages examined suggesting that Alz50 is
labeling similar populations of neurons.
Unlike previous studies where various phosphotau epi-
topes were immunohistochemically detectable by 15 months
of age in 3xTg-AD mice [12, 17, 49], we observed tau-
ir neurons primarily in the ventral CA1 hippocampal
pyramidal and subicular neurons at 3-weeks of age. This
occurred well before the onset of plaque deposition in
8-9-month-old 3xTg-AD mice [17]. The current ﬁndings
indicate that intraneuronal amyloid and tau co-occur or
appear concurrent in the same neurons at least as early
as 3 weeks of age suggesting that these mutant mice are
born with the dual expression of these proteins within select
populations of brain cells. The early appearance of tau-ir
neurons in the forebrain of 3xTg-AD mice is not surprising
since overexpression of mutant P301L four repeat tau and
the APPswe amyloid mutation together [59] or tau P301L
alone [60] induces an age dependent onset of MC1, AT8, and
PHF-irneuroﬁbrillarytangles(NFTs)inthetelencephalonof
mutant mice as young as 2.5 months of age [60].
However, it remains to be determined whether amyloid
interacts with tau over time to induce the apparent age-
related perikaryal degeneration seen in these mice. Studies
are underway to test the hypothesis that depletion of
intraneuronal amyloid at an early age would prevent or slow
the degeneration of neurons in these mice. It is interesting
to note that tau containing straight ﬁlaments were seen in
18–20-month-old mutant mice suggesting that late-stage tau
neuronal aggregation also plays a key role in the ultimate
demise of neurons in 3xTg-AD mice. Although no studies
to date have shown frank neuronal cell loss, a recent report
described a reduction in the number of neurons containing
6E10 and tau markers in the brainstem of these mutant mice
[15].
To more fully understand the vulnerability of hippocam-
pal complex neurons, we colocalized 6E10 and Alz50 using
immunoﬂuorescence. A previous study colocalized HT7,International Journal of Alzheimer’s Disease 21
a human speciﬁc pan tau antibody and M71/3 (oligomeric
Aβ) in the dorsal hippocampus in 3xTg-AD mice [3].
However, at earlier ages conformation or phosphospeciﬁc
tau antibodies were not evaluated. Our immunoﬂuores-
cencecolocalizationexperimentsdemonstratedthatvirtually
all ventral CA1 pyramidal but not all subicular neurons
contained both Alz50 and 6E10 from 3 weeks to at least
18–20 months of age, suggesting that CA1 neurons are
more vulnerable to Alz50 pathology. Although we were
unable to perform colocalization experiments between 6E10
and our tau antibodies, we performed a comparative light
microscopic analysis of adjacent hippocampal sections. This
study revealed AT180 and AT8-ir neurons in the caudal
aspects of the subicular region where we failed to visualize
Alz50-ir neurons across all ages examined. The reason
for the selective appearance of AT180 and AT8 in the
ventral subiculum remains unknown. One possibility is that
neuroﬁbrillary pathology proceeds according to a sequence
of tau conformational and phosphorylation events [61–
64], which may vary between neuronal populations. In
AD, as tau transitions to a more hyperphosphorylated
state, it undergoes a self-assembly process forming PHF
structures reducing the microtubule stability of the neuronal
cytoskeleton [65, 66]. More speciﬁcally, the evolution of
NFTs in AD follows a progression of phosphorylated tau
modiﬁcations from TG3 (phosphospeciﬁc at Thr231), found
in preneuroﬁbrillary tangles (preNFTs), to AT8 and PHF-
1 in intraneuronal and extraneuronal NFTs [61]. This
progression may be dynamic since intraneuronal AT180 and
AT8 precedes Alz50 tau formation before the appearance
of ﬁbrillar tau [63, 64]. We suggest that the sequence of
cellular tau conformation and phosphorylation events may
also be dynamic in 3xTg-AD mice since Alz50-ir neurons
were found only in CA1 neurons in the hippocampus but
not in the underlying subiculum.
Despite diﬀerences in tau intraneuronal epitope expres-
sion, we found age-related changes in neuronal morphology
in the 3xTg-AD mouse to be similar to the NFT neuronal
phenotypes described in the human AD brain [67, 68].
Some AT8-ir neurons at 9 months of age displayed blunted
dendrites (see Figure 8(e)) or tortuous proximal dendrites
and thickened perinuclear staining reminiscent of Braak
type 2 neurons [67]. In our aged mutant mice, proximal
and distal dendrites lost AT8 immunoreactivity and neurons
appeared more globose and dystrophic similar to Braak type
3 neurons, which accumulate ﬁbrillar material in the human
AD brain [67]. Furthermore, the present ultrastructural
analysis revealed, for the ﬁrst time, the presence of AT8
and Alz50 positive straight tau ﬁlamentous aggregates in
female aged 23-month-old, but not in young or middle-
age 3xTg-AD mice of the same gender, which are similar
to those seen in tangle bearing neurons in the human AD
brain. Similar tau ﬁlaments have been described in single
transgenic mice overexpressing the mutant P301L human
tau gene [10, 59] as well as in the double mutant (TAPP)
mouse expressing APPswe and P301L mutant forms of tau
[59]. NFT formation was enhanced in young and middle age
TAPP mutant mice with respect to single tau transgenic mice
[59]. Although young and middle-aged 3xTg-AD mice carry
thesameAPPswe,andT au P301L mutationsastheTAPPmouse,
3xTg-AD mice did not accumulate ﬁlamentous aggregates
at younger ages. In this regard, mice overexpressing human
genomic and cDNA tau genes also do not display intra-
neuronal ﬁlamentous structures at young ages [69]. These
ﬁndings suggest that factors other than the accumulation of
tau underlie the ﬁlamentous tangle bearing phenotype seen
in human AD. Factors that may inﬂuence the formation of
AD ﬁlaments include diﬀerences in the abundance or ratio
of speciﬁc tau isotypes [70]i nd i ﬀerent cohorts of neurons
and/or minor alterations in proteases, kinases, phosphatases
that alter the structure of these proteins during the life span
of the neuron [25], and/or the promoter system designed
for speciﬁc transgene expression in particular brain regions.
Since age is a major risk factor for AD, aging itself may be a
crucial variable in the formation of intraneuronal ﬁlaments
in 3xTg-AD mice. Despite diﬀerences in the evolution of tau
biochemistry, there are morphological similarities between
neurons containing tau in 3xTg-AD mice and human AD
indicating the usefulness of these mice for studies of the
mechanism(s) underlying select aspects of AD pathology.
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